Fever and pain sell every day in every market, but the sourcing decision behind them is rarely simple. A distributor launching an antipyretic and analgesic range must decide which forms belong in a retail basket, which stay behind the pharmacy counter and which go to hospitals as sterile injectables — each group carries a different document, packaging and validation burden. This guide sets out how to structure that request, what to specify in it, and what a GMP manufacturer should hand you with the first shipment.
The short answer
Procure the category as a portfolio, not as a single SKU. The Artemisine antipyretic and analgesic line spans 16 products across solid oral, effervescent, liquid, sachet, suppository and sterile injectable presentations, fed by 5,000 tons per year of in-house paracetamol API (DML No. Jin20160069) running into the company’s own finished-dosage lines. That vertical setup matters practically: the API lot is traceable to the finished batch in both directions, and one site can cover a retail basket and a hospital injectable list under a single quality system instead of two.
Ask for three things in writing before comparing any prices: the exact presentation with its pack configuration, the document set required for registration in your market, and a dated lead time against a stated MOQ. Quotations built on different strengths, pack sizes or document sets are not comparable.
Why adult and compound antipyretics are a different sourcing problem
Pediatric fever products are often treated as a separate procurement exercise, and rightly so — liquid concentrations, dosing devices and palatability dominate the technical conversation. Adult and compound products invert those priorities. Solid orals are a price-per-unit and pack-format decision. Compound cold-and-flu products are a formulation and registration decision. Hospital injectables are a sterile-manufacturing and dossier decision. Buyers who push all three channels through one undifferentiated request usually end up with quotations that mix categories and documents, then lose weeks reconciling them.
- Format mismatch is the first trap. A request for “paracetamol” can mean 500 mg tablets, effervescent tablets, a 325 mg oral solution or a sterile 500 mg/5 mL ampoule. Those are different production lines, different packs and different registration files.
- Compound SKUs carry more than one active ingredient. Copara compound tablets combine paracetamol 500 mg with diphenhydramine hydrochloride 5 mg and chlorphenamine maleate 2 mg, and the sachet paracetamol, vitamin C and chlorpheniramine granules combine paracetamol 160 mg, ascorbic acid 50 mg and chlorpheniramine maleate 1 mg. Every component has to be declared, specified and tested — a different conversation from a single-ingredient tablet.
- Channel rules differ by market. Retail OTC baskets, pharmacy-counter lines and hospital formulary injectables face different labelling, packaging and submission expectations in the destination country.
- Continuity is judged across the whole list. A buyer sourcing four SKUs from four plants inherits four different supply timelines and four different quality histories.
Seven dimensions to specify before you request a quotation
1. Decide the channel before the molecule
Start with where the product will be dispensed, then choose the presentation. Adult retail lines — plain paracetamol 500 mg tablets, ibuprofen 100 mg tablets, diclofenac sodium 50 mg tablets and aspirin 300 mg tablets — are sold in blister, bottle or box packs that differ from market to market. Write the intended channel against each SKU and the specification tightens immediately.
2. Specify the pack configuration, not just the dosage form
Antipyretic and analgesic presentations from Artemisine are supplied in configurations customised per market requirement — bottle, blister or box — and the granules line ships as 10 sachets per box. A quotation naming only the tablet count leaves the pack, the artwork and the approval cycle undefined. Specify pack configuration and labelling language at RFQ stage: artwork adaptation is one of the slowest steps in a market launch, and it is decided early.
3. Treat compound cold-and-flu products as a formulation project
Compound cold products exist because this part of demand is driven by format and brand rather than by a single molecule, which makes specification heavier. The ratio of the actives, the flavour, the sachet count, the excipient profile and local labelling must be settled together, with each component assessed and reflected in the dossier. Where a market already has an established format, adapting an existing product to local labelling is usually faster than originating a new blend — and Artemisine supports OEM and private-label projects covering formulation, packaging and documentation.
4. Effervescent and sachet granules: humidity is the hidden variable
Effervescent tablets dissolve on contact with water, so in-pack stability depends on keeping moisture out; sachets have the opposite requirement, since the powder must disperse cleanly and hold a consistent dose. These are routine requests for a solid-oral plant, and the reason to ask for stability data rather than assume it. Artemisine runs stability programmes per ICH Q1A and WHO guidelines, with long-term studies at 25 °C / 60 % RH and accelerated studies at 40 °C / 75 % RH in qualified chambers, and at least one batch per product per year entering the continuing stability programme.
5. Injectable analgesics are a sterile project
For hospital channels the sterile line changes the audit completely. Artemisine fills ampoules in a Grade A zone with Grade B background, inside cleanrooms graded A to D per WHO GMP, with Water for Injection produced by three-stage reverse osmosis followed by multi-effect distillation and a hot circulation loop above 70 °C, plus online conductivity and TOC monitoring and offline microbial and endotoxin testing. Where a hospital list includes paracetamol injection 500 mg/5 mL and diclofenac sodium injection 75 mg/3 mL, ask for the sterile file specifically — water system validation summary, batch release testing, container-closure information — rather than accepting a solid-oral file as equivalent.
6. Get the document package specified per SKU
The document set is where most registration timelines are won or lost. Every batch ships with a Certificate of Analysis, and for registration Artemisine provides COPP, DMF and CTD-format dossiers supported by HPLC and GC results, GMP certificates, water system validation summaries, stability data and quality agreements, with legalisation support where the destination authority requires it. On-site and remote audits are welcome, and the Artemisine quality documentation covers a documented pharmaceutical quality system with root-cause deviation handling and CAPA, risk-assessed change control, annual product quality review, independent QA batch release and scheduled self-inspection — what a stringent authority or donor auditor will usually ask to see.
7. Fix MOQ, pack and lead time in one written line
MOQ depends on the product, its strength, the packaging and the destination market. Regular catalogue items are held in stock for fast delivery, while bulk annual programmes are quoted against the specific presentation and pack configuration. The practical step is to send product name, target quantity and destination market once, and require a dated answer covering current stock, MOQ and lead time — the Artemisine export team confirms those within 24 hours.
What Artemisine can supply in this line
Artemisine Medicines Technology is a Chinese pharmaceutical manufacturer and exporter working in R&D, GMP production and global supply of APIs, finished dosage forms and healthcare products; the company profile records that all goods meet USP and BP standards with complete certification and registration documentation for worldwide markets. For this category that means 2 billion tablets per year, 50 million granule sachets per year and 300 million ampoule injections per year, plus paracetamol API at 5,000 tons per year under DML No. Jin20160069. Products are released to BP and enterprise standards and shipped with COA, COPP, DMF and CTD dossiers for OTC registration across the 50+ countries the company serves.
The depth that matters to a buyer is coverage of the whole category rather than a count of SKUs: plain and effervescent paracetamol, adult and pediatric liquid forms, suppositories, compound cold sachets and tablets, and the injectable analgesics a hospital formulary needs — from one site, one quality system and one documentation format.
A practical procurement checklist
- List the SKUs by channel and pack — retail, pharmacy counter, hospital — before listing molecules.
- Write each presentation in full: strength, dosage form, pack configuration, labelling language.
- State the document set you need per SKU, and in which language, before asking for price.
- Request the sterile file separately for any injectable in the list, including water system validation.
- Confirm capacity and lead time against a dated answer, and check that the MOQ answer covers the whole basket rather than one SKU.
- Review the quality evidence: GMP certificate, stability programme, retention samples kept one year beyond expiry, batch traceability in both directions.
- Ask for the artwork and packaging plan, including whether OEM or private-label documentation is required.
- Agree the inspection route early — on-site or remote — together with the destination authority’s legalisation requirements.
Next step
Send the target market, the SKU list with strengths and pack configurations, and the annual volume. The Artemisine export team answers with current stock, MOQ and a dated lead time within 24 hours, and follows up with the COA, COPP, DMF and CTD dossier set for the products you select.
Frequently asked questions
Can Artemisine supply a complete adult antipyretic and analgesic range from one site?
Yes. The antipyretic and analgesic line covers 16 products: paracetamol 500 mg tablets, paracetamol effervescent tablets 500 mg, Copara compound tablets (paracetamol 500 mg + diphenhydramine hydrochloride 5 mg + chlorphenamine maleate 2 mg), paracetamol and vitamin C and chlorpheniramine granules (paracetamol 160 mg + ascorbic acid 50 mg + chlorpheniramine maleate 1 mg), ibuprofen 100 mg tablets, aspirin 300 mg tablets, diclofenac sodium 50 mg tablets, paracetamol injection 500 mg/5 mL and diclofenac sodium injection 75 mg/3 mL, alongside pediatric syrups, oral solutions, suspensions and suppositories. Capacity covers 2 billion tablets per year, 50 million granule sachets per year and 300 million ampoule injections per year, fed by 5,000 tons per year of in-house paracetamol API under DML No. Jin20160069.
Which documents can I use to register an adult analgesic product?
Every batch ships with a Certificate of Analysis (COA). For market registration Artemisine provides COPP, DMF and CTD-format dossiers, supported by HPLC and GC results, GMP certificates, water system validation summaries, stability data (ICH Q1A and WHO guidelines: long-term 25 °C / 60 % RH and accelerated 40 °C / 75 % RH in qualified chambers) and quality agreements, with legalisation support where the destination authority requires it. Retention samples of every commercial batch are kept one year beyond the labelled expiry date, and on-site or remote audits are welcome.
What is the MOQ and lead time for adult analgesic and compound cold products?
MOQ and lead time depend on the product, its strength, the packaging and the destination market. Regular catalogue items are held in stock for fast delivery, and bulk annual programmes are quoted against the specific presentation and pack configuration. Send the product name, target quantity and destination market to the Artemisine export team, which confirms current stock, MOQ and a dated lead time within 24 hours.
Source: dosing and clinical reference summarised from the WHO Model Formulary and WHO Model List of Essential Medicines, World Health Organization; manufacturing, capacity and quality facts from Artemisine GMP documentation. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.
Artemisine Medicines